#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Plasma cell myeloma refractory Neuroendocrine carcinoma metastatic Krabbe's disease Pancreatic carcinoma metastatic Neuroblastoma recurrent Deafness Henoch-Schonlein purpura Congenital ectodermal dysplasia Idiopathic pulmonary fibrosis B-cell type acute leukaemia Chronic hepatitis B Alexander disease Hereditary angioedema Hydrocephalus Gestational trophoblastic tumour More trials…

    Learn about Rare Diseases

    Kearns-Sayre syndrome MELAS syndrome – Treatment Hepatoblastoma – Basic Information Haemophagocytic lymphohistiocytosis Familial amyotrophic lateral sclerosis – Diagnostics Extranodal marginal zone B-cell lymphoma (MALT type) – Treatment Gaucher’s disease type III Ewing’s sarcoma Mucopolysaccharidosis III – Treatment Synovial sarcoma metastatic – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ttf-Ngr Loncastuximab Tesirine L-Lysine Hydrochloride Tyra-300-B01 Sildenafil Citrate Acoramidis Hydrochloride Oritavancin Sulpiride Plasma Aprepitant Lithium Sulphate, Anhydrous Dabrafenib DISODIUM PHOSPHATE Donidalorsen 89ZR-CED88004S (-)-PHENSERINE TARTRATE Flucloxacillin Topotecan Hydrochloride Alectinib TEV-53408 More therapies…

    Learn about Your Condition

    Gender dysphoria Hyperparathyroidism primary Pneumonia chlamydial Synovial sarcoma metastatic Chronic lymphocytic leukaemia Tertiary adrenal insufficiency Red blood cell abnormality Monogenic diabetes Huntington's disease Endocarditis bacterial Eye inflammation Pain Renal injury Injury Left ventricular dysfunction More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Neoplasm

  • Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Patients Under 18 With Relapsed or Refractory Solid Tumors

    Recruiting

    1 1 1
    Investigated Drugs:
    • Ifinatamab Deruxtecan
    Belgium Denmark France Germany Hungary Italy +2

  • Telisotuzumab Adizutecan for Locally Advanced or Metastatic Solid Tumors with MET Amplification in Patients 12 Years and Older

    Recruiting

    2 1 1
    Investigated Diseases:
    • Neoplasm
    Denmark France Spain

  • EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Pembrolizumab
    Austria Finland France Germany Italy Norway +3

  • Volrustomig in Patients with Unresectable Pleural Mesothelioma and Esophageal Squamous Cell Carcinoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Cisplatin
    • Fluorouracil
    • Infliximab
    Germany Italy

  • Phase 1/2A Study of OTP-01 to Evaluate Safety and Anti‑Tumor Activity in Patients with Advanced Solid Tumors

    Recruiting

    2 1 1
    Investigated Diseases:
    • Neoplasm
    • Neoplasm malignant
    Ireland Portugal Spain

  • A study of RPTR-1-201 and pembrolizumab in patients with advanced solid tumors

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Pembrolizumab
    • RPTR-1-201
    France Ireland Portugal Spain
1 2 3 … 25
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!